A Study of Belzutifan (MK-6482) and Metformin in Healthy Adult Participants (MK-6482-039)

Launched by MERCK SHARP & DOHME LLC · Aug 12, 2025

Keywords

ClinConnect Summary

This clinical trial is studying how a medicine called belzutifan (also known as MK-6482) affects the way the body handles another medicine called metformin in healthy adults. Metformin is commonly used to treat diabetes, and researchers want to see if taking belzutifan changes the amount of metformin in the blood and urine over time. Participants will first take metformin alone, and then take metformin together with belzutifan, so scientists can compare the differences.

To join this study, you need to be a healthy adult who doesn’t smoke and has a body weight within a certain range. You should be able to swallow several tablets at once. People with a history of cancer, anemia (low red blood cells), or certain blood acid problems won’t be able to participate. The study is currently not recruiting participants yet. If you join, you can expect to take the medicines as directed and have blood and urine tests to monitor how your body processes the drugs. This study helps researchers understand how these medicines work together, which is important for future treatments.

Gender

ALL

Eligibility criteria

• The main inclusion criteria include, but are not limited to:
• • Is a continuous non-smoker for at least 3 months prior to dosing
• • Has body mass index (BMI) ≥ 18.0 and ≤ 42.0 kg/m2
• • Is able to swallow multiple tablets
• The main exclusion criteria include, but are not limited to:
• • Has a history of cancer (malignancy)
• • Has a history of anemia within the last 5 years
• • Has a known history or presence of metabolic acidosis, ketoacidosis, or lactic acidosis
• • Has a hemoglobin level below the lower limit of normal
• • Has a pulse oximetry reading less than 92% at rest
• • Is known to be a cytochrome P450 (CYP2C19) poor metabolizer or likely poor metabolizer based on genotyping prior to the screening visit or is determined to be a CYP2C19 poor metabolizer